The rise of Sildenafil initially fueled a period of growth for major pharmaceutical companies, but recent shifts present a murky scenario for those considering a stake. Lower-cost versions are eating into earnings, and https://martinaknxh538266.izrablog.com/41535274/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-investment